DJIA 18,259.68 -26.06 -0.14%
NASDAQ 5,092.78 1.98 0.04%
S&P 500 2,129.72 -1.10 -0.05%
market minute promo

Gilead Sciences (NASDAQ: GILD)

112.51 1.29 (1.16%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $112.49 1.14%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $110.70
Previous Close $111.22
Daily Range $110.70 - $112.66
52-Week Range $78.50 - $116.83
Market Cap $165.3B
P/E Ratio 12.67
Dividend (Yield) $1.72 (1.5%)
Ex-Dividend Date
Dividend Pay Date
06/12/15
06/29/15
Volume 6,277,184
Average Daily Volume 11,216,000
Current FY EPS $11.04

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Kite Pharma Starts Dosing in Phase I/II Study on KTE-C19 - Analyst Blog

J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog

Bristol-Myers' HCV Combination Designation Amended by FDA - Analyst Blog

Bristol-Myers' HCV Combination Designation Amended by FDA - Analyst Blog

Achillion Pharmaceuticals: Should You Buy After The Sell-Off?

Gilead, Merck And Achillion/J&J Square Off In An HCV 'Nuc'lear Showdown

MannKind, Front and Center: The Best Product Doesn’t Always Equal the Best Stock

The Motley Fool's own Michael Douglass and Todd Campbell dig into MannKind Corp.'s first quarter earnings to see if MannKind is a bargain, or a bust.

What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Following Hepatitis C, This Could Be the Next Disease Researchers Cure

With an effective cure for hepatitis C now in place after decades of research, we asked three of our top healthcare analysts which disease they believed researchers may cross off the list next. Here's what they had to say.

See More GILD News...

GILD's Top Competitors

GILD $112.51 (1.16%)
Current stock: GILD
AMGN $164.27 (0.26%)
Current stock: AMGN
CELG $116.27 (0.06%)
Current stock: CELG
$0.00 (0.00%)
Current stock: